drugset / Trial / NCT02181972

Efficacy and Safety of Ginkgo Biloba in Middle-aged Cognitively Intact Adults

NCT02181972

Phase 3 Completed 120 enrolled Boehringer Ingelheim
RandomizedParallel-groupDouble-blindTreatment

Summary

The primary objective of this study was to assess the efficacy and safety of Gingko biloba film-coated tablets in improving cognitive function and neuropsychological functioning of middle-aged cognitively intact adults.

Timeline

Start
2002-05
Primary completion
2002-11
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Gingko Biloba Unknown 120 mg Oral

Indications

No indication recorded.